Lund, Sweden · Founded 2019 · Privately Held (backing)
Developer of a biopharmaceutical platform intended to develop proprietary peptides for the prevention and treatment of wounds and topical applications. Xinnate is based in Lund, Sweden and was founded in 2019. Its last reported valuation was $38.8 million in Dec 2022. It has raised $16.1 million.
Last reported valuation
$38.8M
Oct 2026
Priced at
—
Total raised
$16.1M
Last round
—
Cap table — not yet on record
Xinnate's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Xinnate with a free account
·Watch Xinnate: the Monday email on marks, rounds and moves
